USA - NYSE:PBH - US74112D1019 - Common Stock
The current stock price of PBH is 59.95 USD. In the past month the price decreased by -1.72%. In the past year, price decreased by -25.41%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
PRESTIGE CONSUMER HEALTHCARE
660 White Plains Rd.
Tarrytown NEW YORK 10591 US
CEO: Ronald M. Lombardi
Employees: 570
Phone: 19145246800
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
The current stock price of PBH is 59.95 USD. The price decreased by -2.3% in the last trading session.
PBH does not pay a dividend.
PBH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PBH.
PRESTIGE CONSUMER HEALTHCARE (PBH) will report earnings on 2026-02-04, before the market open.
You can find the ownership structure of PRESTIGE CONSUMER HEALTHCARE (PBH) on the Ownership tab.
ChartMill assigns a fundamental rating of 6 / 10 to PBH. Both the health and profitability get an excellent rating, making PBH a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months PBH reported a non-GAAP Earnings per Share(EPS) of 4.56. The EPS increased by 13.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.02% | ||
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| Debt/Equity | 0.55 |
10 analysts have analysed PBH and the average price target is 82.42 USD. This implies a price increase of 37.47% is expected in the next year compared to the current price of 59.95.
For the next year, analysts expect an EPS growth of 0.67% and a revenue growth -2.36% for PBH